Daiichi Sankyo Co. Ltd., of Tokyo, agreed to acquire a license to the Azymetric and Effector Function Enhancement and Control Technology , or EFECT, platforms developed by Zymeworks Inc., of Vancouver, British Columbia, to develop a bispecific antibody.